Grohar statistics

To access cutting-edge analytics on consensus tools, life science contexts and associated fields, you will need to subscribe to our premium service.

Subscribe
info

Citations per year

Citations chart
info

Popular tool citations

chevron_left Genome-scale metabolic reconstruction chevron_right
Popular tools chart
info

Tool usage distribution map

Tool usage distribution map
info

Associated diseases

Associated diseases

Grohar specifications

Information


Unique identifier OMICS_28637
Name Grohar
Software type Application/Script
Interface Graphical user interface
Restrictions to use None
Operating system Unix/Linux
Computer skills Medium
Stability Stable
Requirements
Anaconda, cobra, libsmbl, bioservices, PyQt5, pydotplus, cobrababel, python-Levenshtein
Maintained Yes

Download


Versioning


Add your version

Documentation


Maintainer


  • person_outline Moskon Miha <>

Publication for Grohar

Grohar in publications

 (11)
PMCID: 5098094
PMID: 27843394
DOI: 10.1155/2016/7461783

[…] sn-38, a topoisomerase i inhibitor, induces cell death in s-phase. while it shows modest single agent activity [, ], better results have been achieved in combination with other cytotoxic drugs [, ]. grohar et al. recently reported preclinical data of a ewing sarcoma xenograft model, suggesting a strong synergism of trabectedin and irinotecan given sequentially []. trabectedin blocks ews-fli1 […]

PMCID: 5007751
PMID: 27635231
DOI: 10.12688/f1000research.8631.1

[…] transcription, inhibits transcription-coupled nucleotide excision repair, promotes degradation of rna polymerase ii, and generates dna double-strand breaks, leading to s and g 2 cell cycle arrest . grohar et al. demonstrated that ewing sarcoma cell lines, in addition to myxoid liposarcomas, are particularly sensitive to the apoptotic effects of trabectedin compared with other fusion […]

PMCID: 5190040
PMID: 27259270
DOI: 10.18632/oncotarget.9762

[…] targets for bet inhibitors. this strategy can be readily extended to other cancer types initiated by fusion transcription factors., ewing sarcoma cell lines were generous gifts from patrick grohar at van andel research institute. cog-e-352 was a gift from the children's oncology group cell culture/xenograft repository. cells were maintained at 37°c in 5% co2 with rpmi-1640 medium […]

PMCID: 4890991
PMID: 26802024
DOI: 10.18632/oncotarget.6937

[…] olivier delattre reported that ews-fli1 silencing in the in vivo context of a mouse xenograft model resulted specifically in adipogenic differentiation of tumor cells. similarly, patrick grohar observed replacement of the tumor tissue in ewing sarcoma bearing mice by fat tissue of human origin upon treatment with pm01183, a second generation trabectedin analog. this drug, […]

PMCID: 4353378
PMID: 25806369
DOI: 10.3389/fcell.2015.00015

[…] and chla-10 parental cells would exhibit equivalent sensitivities to mithramycin or yk-4-279, both pharmacological agents that have been shown to effectively target and inhibit ews-fli1 activity (grohar et al., ; barber-rotenberg et al., ). cell lines were exposed to mithramycin, yk-4-279, or dmso vehicle for a period of 48 h and mts assays were subsequently performed to determine relative […]


To access a full list of publications, you will need to upgrade to our premium service.

Grohar institution(s)
Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
Grohar funding source(s)
Supported by the scientific-research programme Pervasive Computing (P2-0359) financed by the Slovenian Research Agency.

Grohar reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review Grohar